Treatment outcomes of pulmonary multidrug-resistant tuberculosis; 10 year follow up study

Year 2021, , 26 - 30, 22.01.2021

Hüseyin Arpağ , Murat Yalçınsoy Sinem Güngör Tülin Kuyucu , Nurhan Atilla

https://doi.org/10.38053/acmj.813821

Abstract

ABSTRACT
Aim: Treatment rates of multidrug-resistant tuberculosis (MDR-TB) vary from clinic to clinic. In this study, the characteristics of MDR-TB patients followed in two clinics of our hospital and their relationship with treatment results were investigated.
Material and Method: This observational retrospective cohort study performed in a government hospital which is one of the important reference center for management of tuberculosis in Turkey. Seventy-nine adult MDR-TB cases who'm diagnosed and treated between 2004-2014 were retrospectively enrolled into the study.
Results: Of the patients with MDR-TB, 58 were male, 21 were female, mean age was 36.24 ± 13.75 and all of them were HIV (-). 64 patients completed treatment, 15 patients still under treatment. The average hospitalization time was 162.76. Radiologically, 11 patients had diffuse disease and 68 patients had limited disease. The mean number of patients who received second-line drugs were 5.18 ± 0.5 and drug-related side effects developed in 36 patients. Cure was achieved in 84.4% of the patients, 7.8% discontinued the treatment, 7.8% died during the treatment and there wasn’t any treatment failure.
Conclusion: In our study, we think that the factors that increase the success of MDR-TB treatment are: young age, low resistance to second line medication, prolongation of hospitalization, good compliance with treatment, low rate of ofloxacin use in previous treatment, use of fluoroquinolones in new patients, surgery in selected patients.

Keywords

Multidrug-resistant, pulmonary, tuberculosis

References

• 1. Frieden TR, Fujiwara PI, Washko RM, Hamburg MA. Tuberculosis in New York City-turning the tide. N Engl J Med 1995; 333:229.
• 2. World Health Organization. Global tuberculosis report, Geneva, Switzerland: WHO, 2015.
• 3. Revised definition of extensively drug-resistant tuberculosis. MMWR Morb Mortal Wkly Rep 2006; 55:1176.
• 4. Törün T, Güngör G, Özmen İ et al. Side effects associated with the treatment of multidrug-resistant tuberculosis. Int J Tub Lung Dis 2005; 9:1373–7 2005.
• 5. Ünsal E, Güler M, Ofluoglu R, Capan N, Cimen F. Factors associated with treatment outcome in 64 HIV negative patients with multidrug resistant tuberculosis. J Thorac Dis 2013; 5: 435-9.
• 6. Nadu T, Pauline Joseph I, Bhaskara V et al. Outcome of standardized treatment for patients with MDR-TB. Indian J Med Res 2011; 133: 529–34.
• 7. Khurram M, Tul H, Khaar B, Fahim M. Multidrug-resistant tuberculosis in Rawalpindi, Pakistan. J Infect Dev Ctries 2012; 6: 29-32.
• 8. Chiang CY, Enarson DA, Yu MC et al. Outcome of pulmonary multidrug-resistant tuberculosis: a 6-yr follow-up study. Eur Respir J 2006; 28: 980–985.
• 9. Shin SS, Pasechnikov AD, Gelmanova IY et al. Adverse reactions among patients being treated for MDR-TB in Tomsk, Russia. Int J Tuberc Lung Dis 2007; 11: 1314-20.
• 10. Milanov V, Falzon D, Zamfirova M et al. Factors associated with treatment success and death in cases with multidrug-resistant tuberculosis in Bulgaria, 2009-2010. Int J Mycobacteriol 2015; : 131-7.
• 11. Hirpa S, Medhin G, Girma B, et al. Determinants of multidrug-resistant tuberculosis in patients who underwent first-line treatment in Addis Ababa: a case control study. BMC Public Health 2013;13:782.
• 12. Law WS, Yew WW, Chiu Leung C, et al. Risk factors for multidrug-resistant tuberculosis in Hong Kong. Int J Tuberc Lung Dis 2008; 12: 1065–70.
• 13. Heunis JC, Kigozi NG, van der Merwe S, Chikobvu P, Beyers N. Sex-related trends in non-conversion of new smear-positive tuberculosis patients in the Free State, South Africa. Public health action 2014; 4: 66–71.
• 14. Tahaoğlu K, Törün T, Sevim T, et al. The treatment of multidrug-resistant tuberculosis in Turkey. N Engl J Med 2001; 345: 170-4.
• 15. Park MM, Davis AL, Schluger NW, et al. Outcome of MDR-TB patients, 1983-1993. Prolonged survival with appropriate therapy. Am J Respir Crit Care Med 1996; 153: 317-9.
• 16. Goble M, Iseman MD, Madsen LA, Waite D, Ackerson L, Horsburgh CR Jr. Treatment of 171 patients with pulmonary tuberculosis resistant to Isoniazid and Rifampin. N Engl J Med 1993; 328: 527-532.
• 17. Park SK, Kim CT, Song SD. Outcome of chemotherapy in 107 patients with pulmonary tuberculosis resistant to isoniazid and rifampin. Int J Tuberc Lung Dis 1998; 2: 877-84.
• 18. Yew WW, Chan CK, Chau CH, et al. Outcomes of patients with multidrug-resistant pulmonary tuberculosis treated with ofloxacin/levofloxacin-containing regimens. Chest 2000; 117: 744–751.
• 19. Orenstein EW, Basu S, Shah NS, Andrews JR, Friedland GH, Moll AP. Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis. Lancet Infect Dis 2009; 9: 153–161.
• 20. Ginsburg AS, Grosset JH, Bishai WR. Fluoroquinolones, tuberculosis,and resistance. Lancet Infect Dis 2003; 3: 432–442.
• 21. Grimaldo ER, Tupasi TE, Rivera AB, et al. Increased resistance to ciprofloxacin and ofloxacin in multidrugresistant Mycobacterium tuberculosis isolates from patients seen at a tertiary hospital in the Philippines. Int J Tuberc Lung Dis 2001; 5: 546–550.
• 22. Chan ED, Laurel V, Strand MJ, et al. Treatment and outcome analysis of 205 patients with multidrug-resistant tuberculosis. Am J Respir Crit Care Med 2004; 169: 1103-9.
• 23. Chiang CY, Yu MC, Bai KJ, Lin TP, Lee YC. Pulmonary resection in the treatment of patients with pulmonary multidrug-resistant tuberculosis in Taiwan. Int J Tuberc Lung Dis 2001; 5: 272–277.
• 24. Park SK, Lee CM, Heu JP, Song SD. A retrospective study for the outcome of pulmonary resection in 49 patients with multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2002; 6: 143–149.